The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Guggenheim: Maintaining a "buy" rating on ProMIS Neurosciences ( ProMIS Neurosciences Inc.(PMN.US) ), while raising its price target from $69 to $100.

Benchmark: Maintaining a "buy" rating for Cineverse ( Cineverse Corp. Class A(CNVS.US) ), with a price target raised from $12 to $14.

Cantor Fitzgerald: Upgraded Capricor Therapeutics ( Capricor Therapeutics, Inc.(CAPR.US) ) to "overweight", raising the price target from $3.50 to $28.

Seaport Global: Initial rating for ADI Global Distribution ( ADI Global Distribution Inc.(ADIG.US) ) stock at "Buy", with a target price of $35.

Piper Sandler: Maintaining an "overweight" rating on Gossamer Bio Gossamer Bio(GOSS.US) ), while lowering the price target from $15 to $4.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
ProMIS Neurosciences Inc.(PMN.US)	to lift	$100.0	$14.86	572.95%	Guggenheim
Cineverse Corp. Class A(CNVS.US)	to lift	$14.0	$2.69	420.45%	Benchmark
Capricor Therapeutics, Inc.(CAPR.US)	to lift	$28.0	$6.65	321.05%	Cantor Fitzgerald
Sagimet Biosciences(SGMT.US)	to lift	$29.0	$10.55	174.88%	Citizens
Creative Realities, Inc.(CREX.US)	to lift	$8.0	$3.28	143.9%	Ladenburg Thalmann
ADI Global Distribution Inc.(ADIG.US)	Initial classification	$35.0	$21.24	64.78%	Seaport Global
Gossamer Bio(GOSS.US)	cut	$4.0	$0.1542	2494.03%	Piper Sandler
NextNRG(NXXT.US)	cut	$1.5	$0.2672	461.38%	HC Wainwright & Co.
Femasys, Inc.(FEMY.US)	cut	$10.0	$2.29	336.68%	Maxim Group
Veritone, Inc.(VERI.US)	cut	$5.0	$1.15	334.78%	Needham

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

RBC Capital: Maintaining its "Outperform Market" rating for Applied Materials ( Applied Materials, Inc.(AMAT.US) ) stock, while raising its price target from $520 to $600.

JP Morgan: Maintaining an "overweight" rating on Applied Materials ( Applied Materials, Inc.(AMAT.US) ) stock, while raising the price target from $515 to $660.

RBC Capital: Maintaining its "Outperform" rating on Palo Alto Networks Palo Alto Networks, Inc.(PANW.US) ) stock, while raising its price target from $330 to $434.

Wells Fargo: Maintaining a "Market-Similar Weight" rating for SanDisk ( Sandisk Corporation(SNDK.US) ), while raising its price target from $1,400 to $1,550.

RBC Capital: Maintaining a "sector-match" rating for SanDisk ( Sandisk Corporation(SNDK.US) ), while raising its price target from $1,300 to $1,600.

First Coverage

Jefferies: A preliminary rating of "buy" for Aehr Test Systems ( Aehr Test Systems(AEHR.US) ), with a target price of $175.

Leerink Partners: Initial rating for Freenome ( Freenome, Inc.(FRNM.US) ) at "outperforms the market", with a price target of $18.

RBC Capital: Krystal Biotech ( Krystal Biotech, Inc.(KRYS.US) ) has an initial rating of "outperforming the market" with a price target of $400.

reduction

B. Riley Securities: Affirming a "buy" rating for Applied Materials ( Applied Materials, Inc.(AMAT.US) , with a price target cut from $790 to $700.

B of A Securities: Maintaining a "buy" rating on Applied Materials ( Applied Materials, Inc.(AMAT.US) stock, while lowering the price target from $720 to $650.

Morgan Stanley: Maintaining an "overweight" rating on Tapestry ( Tapestry(TPR.US) ), while lowering the price target from $164 to $159.

Needham: Maintaining a "buy" rating on TSS ( TSS, Inc.(TSSI.US) ), while lowering the price target from $16 to $13.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.